Medication Therapy Management Empowerment Act of 2013

To amend title XVIII of the Social Security Act to provide part D eligible individuals with single chronic diseases access to services under medication therapy management programs under the Medicare part D prescription drug program. 1. Short title This Act may be cited as the Medication Therapy Management Empowerment Act of 2013 2. Access to services under medication therapy management programs for Medicare part D eligible individuals with single chronic diseases Section 1860D–4(c)(2)(A) of the Social Security Act ( 42 U.S.C. 1395w–104(c)(2)(A) (1) in clause (ii), by striking subclause (I) and inserting the following: (I) have— (aa) multiple chronic diseases (such as diabetes, asthma, hypertension, hyperlipidemia, and congestive heart failure); or (bb) subject to clause (iii), any single chronic disease, including diabetes, hypertension, heart failure, dyslipidemia, respiratory disease (such as asthma, chronic obstructive pulmonary disease or chronic lung disorder), bone disease-arthritis (such as osteoporosis or osteoarthritis), rheumatoid arthritis, or mental health disorder (such as depression, schizophrenia, or bipolar disorder). ; and (2) by adding at the end the following: (iii) Determinations relating to program costs for including individuals with single chronic diseases (I) Initial determinations With regard to any single chronic disease, clause (ii)(I)(bb) shall only be applied if the Chief Actuary for the Centers for Medicare & Medicaid Services determines that the application of such clause with regard to such disease is not projected to increase overall costs to the Medicare program under this title over the five year period beginning on the date of determination. (II) Review of determinations In the case that clause (ii)(I)(bb) is applied with respect to a single chronic disease pursuant to a determination under subclause (I), not later than five years after such date of determination, the Chief Actuary for the Centers for Medicare & Medicaid Services shall review the effect of the application of such clause with respect to such disease on the actual cost of the Medicare program under this title during such five years. Based on such review, if the Chief Actuary is unable to determine that, with regard to such single chronic disease, the application of such clause did not increase costs to the Federal government under the Medicare program under this title over such period, then the Secretary shall review the findings of the Chief Actuary and determine whether such clause shall continue to be applied with regard to such single chronic disease. In conducting such review and making such determination, the Secretary shall consider the extent to which the application of such clause with regard to such single chronic disease effects the health outcomes of part D eligible individuals and any savings and costs to the Federal government under the Medicare program under this title. .

Summary: Medication Therapy Management Empowerment Act of 2013 - Amends part D (Voluntary Prescription Drug Benefit Program) of title XVIII (Medicare) of the Social Security Act to provide access to services under medication therapy management programs for Medicare part D (Voluntary Prescription Drug Program) eligible individuals with a single chronic disease. Allows the application of this Act only if the Chief Actuary for the Centers for Medicare & Medicaid Services determines that such application with regard to a particular single chronic disease is not projected to increase overall costs to the Medicare program over the following five year period.